Navigation Links
Cancer-Killing Viruses Employ Multiple Mechanisms

The search for safe, effective cancer therapies has led numerous academic and industrial research groups to investigate oncolytic, or cancer-killing viruses//. Oncolytic viruses which include the naturally occurring reovirus, infect cancer cells while sparing healthy tissues. Once inside the tumor cell, the viruses produce thousands of copies of themselves, causing tumor cells to burst. After tumor cells die, viruses clear rapidly from the body without harming the patient.

More recently however, it has been discovered that the reovirus may also have the potential to prime the body’s own immune system to mount a defense against cancer cells. Oncolytics Biotech Inc., a company developing an oncolytic virus treatment based on the reovirus, believes that in addition to directly killing cancer cells, oncolytic viruses may induce a powerful, long-lasting immune response that continues to shrink tumors for weeks or months after the virus is gone. This complementary tumor-killing mechanism is based on the virus acting on specific immune system cells.

The immune system is composed of three “layers” or mechanisms that protect humans from disease. The first line of defense, the skin and mucous membranes, acts as a physical barrier. The second layer is the innate immune system, a broad-acting, short-term, non-specific immune response to pathogens such as bacteria or viruses. Microbes that evade the innate system encounter a third layer of protection; a second, more powerful immune mechanism called the adaptive immune response. Through adaptive immunity, populations of white blood cells known as lymphocytes – B cells and T cells – mount a powerful, highly specific immune system attack on specific pathogens. The adaptive immune responses to virus and bacterial infections, for example, are quite different.

The immune system also protects humans from cancer. In the case of the reovirus, researchers believe the key is the interaction between innat e and adaptive immune responses, specifically communication between dendritic and natural killer cells (part of innate immunity) and certain types of T cells (from the adaptive immune system).

“We’ve understood the mechanism of action of reovirus replication in cancer for a number of years,” explains Dr. Matt Coffey, Chief Scientific Officer at Oncolytics, “but we also observed that often tumors continued to shrink after the virus was gone.” Immunologic work now suggests that reovirus exposure is “educating” the immune system to recognize and kill the same cancer cells that are attacked by reovirus. “If you can teach the immune system to recognize cancer cells, it may be possible to fight off the disease for much longer than we originally anticipated.”

Reovirus is an oncolytic virus that specifically targets tumor cells containing an active form of ras, a genetic mutation found in many types of cancer but not in normal cells. Because of the reovirus genetic makeup, it also appears to activate an immune response that spells double trouble for cancer cells.

Researchers hypothesized that reovirus activation of dendritic cells, which are key to early detection of infection (through the innate immune response), may “instruct” cells belonging to the adaptive immune response, namely natural killer cells and T cells, to attack the tumor even after the virus no longer remains in the body.

Experiments at respected institutions such as St. James University Hospital in Leeds and the Mayo Clinic in Rochester suggest that incubation of reovirus with human dendritic cells led to well-known signs of immune system activation. One of these is the release of cancer-fighting chemicals known as cytokines. Moreover, reovirus did not induce either productive infection (which generates many thousands of copies of the virus) or death in dendritic cells. In other words, although the dendritic cells were technically infected with reovirus, they did not suffer the same fate as cancer cells. In fact, infection actually stimulated the cells to a higher level of cancer-fighting immune activation, as well as priming the cancer-killing ability of natural killer cells and T cells.

These experiments indicate that in addition to killing cancer cells by invading them, the reovirus may support early, innate anti-tumor immunity as well as longer-lasting adaptive immunity against cancer. Discovery of the “immune connection” has lead to a more complete picture of how oncolytic viruses kill cancer cells. If scientists can enhance the anti-tumor immune response, they may be able to make reovirus therapy more effective.

“These results are exciting as they suggest that in addition to directly killing cancer cells in the short term, the reovirus imparts an important cancer-killing ability to the body’s own immune system,” said Dr. Coffey.


Related medicine news :

1. Cancer-Killing Compound From A Fungus
2. New Molecule that can stop the growth of Viruses
3. Screening Of Blood Samples For Viruses
4. Stopping The Growth Of Viruses
5. Stopping The Growth Of Viruses
6. Mutated Viruses Can Cure Tumors
7. Mass Spectrometry to Identify Viruses
8. Safety of Cancer Therapeutic Viruses Enhanced
9. Viruses Can Cross Species Barrier
10. Understanding the Evolution of Viruses a little more Clearly
11. U.S., Australian Scientists Develop Vaccine Against Deadly Viruses
Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: